deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT02020070

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Sponsor: Ferring Pharmaceuticals

Conditions Metastatic Castration Sensitive Prostate Cancer
Interventions Degarelix Ipilimumab Radical Prostatectomy
Updated 15 times since 2017 Last updated: Aug 18, 2025 Started: Dec 18, 2013 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02020070, this PHASE2 trial focuses on Metastatic Castration Sensitive Prostate Cancer and remains ongoing. Sponsored by Ferring Pharmaceuticals, it has been updated 15 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jul 2019 · 12 months · monthly snapshot~Jul 2019 – ~Jul 2020 · 12 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 10 earlier versions

  1. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ferring Pharmaceuticals
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations